Preparing for the digital journey

Fresh off his appearance at this year’s Frontiers Health conference, we sat down with Sandoz’s head of digital Andre Heeg to get his views on where digital pharma is heading and how compani

Chasing Mylan, Hikma tries again with rejected generic Advai...

Sandoz buys Aspen's Japanese generics business for up to $43...

Novartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Aspen in a deal worth up to 400 million euros ($434 million).

FDA finally approves Sandoz's Neulasta biosimilar, but will ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta.

Sandoz says ‘no’ to Pear Therapeutics’ digital apps, handing...

Novartis strikes marketing deal for Polpharma's potential Ty...

Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<